Clinical Trials Logo
NCT number NCT03495973
Study type Observational
Source Janssen-Cilag Ltd.
Contact Study Contact
Phone 844-434-4210
Email JNJ.CT@sylogent.com
Status Recruiting
Phase
Start date October 25, 2017
Completion date January 30, 2021

Clinical Trial Summary

The main purpose of this study is to assess ustekinumab's ability to induce clinical response and remission ("effectiveness") at Week 16 and remission at Week 52 and Week 104 in participants with Crohn's disease (CD). Response and remission will be assessed using clinical parameters. Retention rate at week 52 and 104 will also be studied.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


See also
  Status Clinical Trial Phase
Recruiting NCT03058679 - Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission of Crohn's Disease N/A
Recruiting NCT02871635 - BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity Phase 3
Not yet recruiting NCT02931799 - Prevention of Readmissions at IBD Centres of Excellence N/A
Not yet recruiting NCT02878395 - Genomic/Epigenomic Biomarkers of Deregulation of Immune System in Inflammatory Bowel Diseases N/A
Not yet recruiting NCT02820493 - Effectiveness of Vedolizumab in CD Patients Naïve to Anti-TNF Phase 4
Recruiting NCT02332356 - Therapeutic Optimization Study Based on MR Enterocolonography in Patients With Crohn's Disease Phase 3
Completed NCT02161640 - Vascular Dysfunction in Paediatric IBD N/A
Completed NCT00999115 - Allogenic Stem Cells Derived From Lipoaspirates for the Treatment of Recto-vaginal Fistulas Associated to Crohn`s Disease (ALOREVA) Phase 1/Phase 2
Completed NCT00521950 - Cost-effectiveness of TPMT Pharmacogenetics N/A
Recruiting NCT00383344 - Use of FDG PET/CT to Evaluate Crohn Disease Phase 2
Completed NCT00206674 - Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease Phase 3
Active, not recruiting NCT02513459 - A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab) in Patients With Moderately to Severely Active Crohn's Disease Phase 2
Not yet recruiting NCT03239704 - Improving Outcomes Among Urgent Care Clinic Patients With Inflammatory Bowel Disease N/A
Recruiting NCT03220841 - Stricture Definition and Treatment (STRIDENT) Drug Therapy Study Phase 4
Recruiting NCT03194529 - FMT in Pediatric Crohn's Disease Phase 1/Phase 2
Recruiting NCT03218202 - Stricture Definition and Treatment (STRIDENT) Observational Study. N/A
Recruiting NCT03222011 - Stricture Definition and Treatment (STRIDENT) Endoscopic Therapy Study N/A
Recruiting NCT03171246 - CD-TREAT Diet: a Novel Therapy for Active Luminal Crohn's Disease N/A
Recruiting NCT02956538 - Induced Adult Refractory Active Crohn's Disease Clinical Relieving by Using Thalidomide Phase 0
Recruiting NCT02520843 - An Innovative Treatment for Fistula-in-ano in Crohn Disease : Local Micro Reinjection of Autologous Fat and SVF Phase 1/Phase 2